260
Participants
Start Date
October 18, 2022
Primary Completion Date
October 12, 2026
Study Completion Date
October 12, 2026
CC-92480
Specified dose on specified days
Tazemetostat
Specified dose on specified days
BMS-986158
Specified dose on specified days
Trametinib
Specified dose on specified days
Dexamethasone
Specified dose on specified days
RECRUITING
Memorial Sloan Kettering Cancer Center, New York
RECRUITING
Johns Hopkins Medicine - The Sidney Kimmel Comprehensive Cancer Center, Baltimore
RECRUITING
Hospital Universitario 12 de Octubre, Madrid
RECRUITING
UAB Comprehensive Cancer Center, Birmingham
RECRUITING
Hospital Universitario Marques de Valdecilla, Santander
RECRUITING
Dana-Farber Cancer Institute, Boston
RECRUITING
John Theurer Cancer Center at Hackensack UMC, Hackensack
RECRUITING
Alberta Health Services AHS - Foothills Medical Centre FMC, Calgary
RECRUITING
University of Alberta - Cross Cancer Institute, Edmonton
RECRUITING
University Health Network UHN - Princess Margaret Hospital PMH, Toronto
RECRUITING
Oslo University Hospital, Oslo
RECRUITING
ICO - Hospital Germans Trias i Pujol, Barcelona
RECRUITING
The Christie NHS Foundation Trust, Manchester
WITHDRAWN
Local Institution - 0001, Leicester
WITHDRAWN
Local Institution - 0014, Liverpool
RECRUITING
Churchill Hospital, Oxford
RECRUITING
NIHR UCLH Clinical Research Facility, London
Lead Sponsor
Bristol-Myers Squibb
INDUSTRY